In silico binding mechanism prediction of benzimidazole based corticotropin releasing factor-1 receptor antagonists by quantitative structure activity relationship, molecular docking and pharmacokinetic parameters calculation

References

• Ahuja, V. T. , Hartz, R. A. , Molski, T. F. , Mattson, G. K. , Lentz, K. A. , Grace, J. E. , … Macor, J. E. (2016). Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF 1) receptor antagonists. Bioorganic & Medicinal Chemistry Letters , 26 , 2184–2187. doi:10.1016/j.bmcl.2016.03.067.
   PubMed Web of Science ®Google Scholar
• Ajmani, S. , Jadhav, K. , & Kulkarni, S. A. (2006). Three-dimensional QSAR using the k-nearest neighbor method and its interpretation. Journal of Chemical Information and Modeling , 46 , 24–31. doi:10.1021/ci0501286.
   PubMed Web of Science ®Google Scholar
• Anusuya, S. , & Gromiha, M. M. (2016). Quercetin derivatives as non-nucleoside inhibitors for dengue polymerase: Molecular docking, molecular dynamics simulation, and binding free energy calculation. Journal of Biomolecular Structure and Dynamics , 1–15 , doi:10.1080/07391102.2016.1234416.
   Web of Science ®Google Scholar
• Arvanitis, A. G. , Gilligan, P. J. , Chorvat, R. J. , Cheeseman, R. S. , Christos, T. E. , Bakthavatchalam, R. , … Arnold, C. (1999). Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and-triazines. Journal of Medicinal Chemistry , 42 , 805–818. doi:10.1021/jm980222w.
   PubMed Web of Science ®Google Scholar
• Athar, M. , Lone, M. Y. , Khedkar, V. M. , & Jha, P. C. (2015). Pharmacophore model prediction, 3D-QSAR and molecular docking studies on vinyl sulfones targeting Nrf2-mediated gene transcription intended for anti-Parkinson drug design. Journal of Biomolecular Structure and Dynamics , 34 , 1282–1297. doi:10.1080/07391102.2015.1077343.
   PubMed Web of Science ®Google Scholar
• Badhani, B. , & Kakkar, R. (2016). In silicostudies on potential MCF-7 inhibitors: A combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis. Journal of Biomolecular Structure and Dynamics , 1–18 , doi:10.1080/07391102.2016.1202863.
   Web of Science ®Google Scholar
• Chalmers, D. T. , Lovenberg, T. W. , Grigoriadis, D. E. , Behan, D. P. , & De Souza, E. B. (1996). Corticotrophin-releasing factor receptors: From molecular biology to drug design. Trends in Pharmacological Sciences , 17 , 166–172. doi:10.1016/0165-6147(96)81594-x
   PubMed Web of Science ®Google Scholar
• de Da Silva, C. H. T. de P. , & Taft, C. A. (2016). 3D descriptors calculation and conformational search to investigate potential bioactive conformations, with application in 3D-QSAR and virtual screening in drug design. Journal of Biomolecular Structure and Dynamics , 1–9 . doi:10.1080/07391102.2016.1237382
   Web of Science ®Google Scholar
• Diniz, E. M. L. P. , de Paula, Tomich , da Silva, C. H. , Gómez-Perez, V. , Federico, L. B. , & Campos Rosa, J. M. (2016). GRIND2-based 3D-QSAR and prediction of activity spectra for symmetrical bis-pyridinium salts with promastigote antileishmanial activity. Journal of Biomolecular Structure and Dynamics , 1–11 . doi:10.1080/07391102.2016.1221364
   Web of Science ®Google Scholar
• Dzierba, C. D. , Hartz, R. A. , & Bronson, J. J. (2008). Recent advances in corticotropin-releasing factor receptor antagonists. Annual Reports in Medicinal Chemistry , 43 , 3–23. doi:10.1016/s0065-7743(08)00001-8.
   Web of Science ®Google Scholar
• Friesner, R. A. , Banks, J. L. , Murphy, R. B. , Halgren, T. A. , Klicic, J. J. , Mainz, D. T. , … Shaw, D. E. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry , 47 , 1739–1749. doi:10.1021/jm0306430.
   PubMed Web of Science ®Google Scholar
• Friesner, R. A. , Murphy, R. B. , Repasky, M. P. , Frye, L. L. , Greenwood, J. R. , Halgren, T. A. , … Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry , 49 , 6177–6196. doi:10.1021/jm051256o.
   PubMed Web of Science ®Google Scholar
• Ghose, A. K. , Herbertz, T. , Hudkins, R. L. , Dorsey, B. D. , & Mallamo, J. P. (2011). Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS chemical neuroscience , 3 , 50–68. doi:10.1021/cn200100 h.
   PubMed Web of Science ®Google Scholar
• Gilligan, P. J. , He, L. , Clarke, T. , Tivitmahaisoon, P. , Lelas, S. , Li, Y. W. , … Trainor, G. (2009). 8-(4-Methoxyphenyl) pyrazolo [1, 5-a]-1, 3, 5-triazines: Selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. Journal of Medicinal Chemistry , 52 , 3073–3083. doi:10.1021/jm9000242.
   PubMed Web of Science ®Google Scholar
• Gilligan, P. J. , & Li, Y. W. (2004). Corticotropin-releasing factor antagonists: Recent advances and exciting prospects for the treatment of human diseases. Current Opinion in Drug Discovery & Development , 7 , 487–497. Retrieved from http://europepmc.org/abstract/med/15338958
   PubMed Web of Science ®Google Scholar
• Golbraikh, A. , & Tropsha, A. (2002). Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Molecular Diversity , 5 , 231–243. doi:10.1023/a:1021372108686.
   PubMed Web of Science ®Google Scholar
• Goyal, S. , Dhanjal, J. K. , Tyagi, C. , Goyal, M. , & Grover, A. (2014). Novel fragment-based QSAR modeling and combinatorial design of pyrazole-derived CRK3 Inhibitors as potent antileishmanials. Chemical Biology & Drug Design , 84 , 54–62. doi:10.1111/cbdd.12290.
   PubMed Web of Science ®Google Scholar
• Grigoriadis, D. E. , Haddach, M. , Ling, N. , & Saunders, J. (2001). The CRF receptor structure, function and potential for therapeutic intervention. Current Medicinal Chemistry-Central Nervous System Agents , 1 , 63–97. doi:10.2174/1568015013358734.
   Google Scholar
• Hauger, R. L. , Risbrough, V. , Oakley, R. H. , Olivares-Reyes, J. A. , & Dautzenberg, F. M. (2009). Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Annals of the New York Academy of Sciences , 1179 , 120–143. doi:10.1111/j.1749-6632.2009.05011.x.
   PubMed Web of Science ®Google Scholar
• Hayes, J. M. , Stein, M. , & Weiser, J. (2004). Accurate calculations of ligand binding free energies: Chiral separation with enantioselective receptors. The Journal of Physical Chemistry A , 108 , 3572–3580. doi:10.1021/jp0373797.
   Web of Science ®Google Scholar
• Hollenstein, K. , Kean, J. , Bortolato, A. , Cheng, R. K. , Doré, A. S. , Jazayeri, A. , … Marshall, F. H. (2013). Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature , 499 , 438–443. doi:10.1038/nature12357.
   PubMed Web of Science ®Google Scholar
• Holsboer, F. (1999). The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Journal of Psychiatric Research , 33 , 181–214. doi:10.1016/s0022-3956(98)90056-5.
   PubMed Web of Science ®Google Scholar
• Ioakimidis, L. , Thoukydidis, L. , Mirza, A. , Naeem, S. , & Reynisson, J. (2008). Benchmarking the reliability of QikProp. Correlation between experimental and predicted values. QSAR & Combinatorial Science , 27 , 445–456. doi:10.1002/qsar.200730051.
   Google Scholar
• Jorgensen, W. L. (2009). Efficient drug lead discovery and optimization. Accounts of Chemical Research , 42 , 724–733. doi:10.1021/ar800236t.
   PubMed Web of Science ®Google Scholar
• Li, J. , Abel, R. , Zhu, K. , Cao, Y. , Zhao, S. , & Friesner, R. A. (2011). The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins: Structure, Function, and Bioinformatics , 79 , 2794–2812. doi:10.1002/prot.23106.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods , 44 , 235–249. doi:10.1016/s1056-8719(00)00107-6.
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. , Lombardo, F. , Dominy, B. W. , & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews , 64 , 4–17. doi:10.1016/j.addr.2012.09.019.
   Web of Science ®Google Scholar
• Macalino, S. J. Y. , Gosu, V. , Hong, S. , & Choi, S. (2015). Role of computer-aided drug design in modern drug discovery. Archives of Pharmacal Research , 38 , 1686–1701. doi:10.1007/s12272-015-0640-5.
   PubMed Web of Science ®Google Scholar
• Maestro , v10.4. (2015). Schrodinger, LLC, NY.
   Google Scholar
• Malik, R. , Mehta, P. , Srivastava, S. , Choudhary, B. S. , & Sharma, M. (2016). Structure-based screening, ADMET profiling and molecular dynamic studies on mGlu2 receptor for identification of newer antiepileptic agents. Journal of Biomolecular Structure and Dynamics , 1–16 .doi:10.1080/07391102.2016.1257440
   Web of Science ®Google Scholar
• Mochizuki, M. , Kori, M. , Kobayashi, K. , Yano, T. , Sako, Y. , Tanaka, M. , … Pratt, S. A. (2016). Design and synthesis of benzimidazoles as novel corticotropin-releasing factor 1 receptor antagonists. Journal of Medicinal Chemistry , 59 , 2551–2566. doi:10.1021/acs.jmedchem.5b01715
   PubMed Web of Science ®Google Scholar
• Owens, M. J. , & Nemeroff, C. B. (1991). Physiology and pharmacology of corticotropin-releasing factor.  Pharmacological reviews ,  43 , 425–473. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/1775506
   Google Scholar
• Patil, R. , Das, S. , Stanley, A. , Yadav, L. , Sudhakar, A. , & Varma, A. K. (2010). Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS ONE , 5 , e12029. doi:10.1371/journal.pone.0012029.
   PubMed Web of Science ®Google Scholar
• Pawar, V. , Lokwani, D. , Bhandari, S. , Mitra, D. , Sabde, S. , Bothara, K. , & Madgulkar, A. (2010). Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies. Bioorganic & Medicinal Chemistry , 18 , 3198–3211. doi:10.1016/j.bmc.2010.03.030.
   PubMed Web of Science ®Google Scholar
• Pradhan, J. , & Goyal, A. (2016). Synthesis, anticonvulsant activity and QSAR studies of some new pyrazolyl pyridines. Medicinal Chemistry Research , 25 , 1639–1656. doi:10.1007/s00044-016-1597-8.
   Web of Science ®Google Scholar
• Rivier, J. , Rivier, C. , & Vale, W. (1984). Synthetic competitive antagonists of corticotropin-releasing factor: Effect on ACTH secretion in the rat. Science , 224 , 889–891. doi:10.1126/science.6326264.
   PubMed Web of Science ®Google Scholar
• Sharaf, M. A. , Illman, D. L. , & Kowalski, B. R. (1986).  Chemometrics  (Vol. 82). John Wiley & Sons. doi:10.1002/cem.1180010409
   Google Scholar
• Sinha, S. , Tyagi, C. , Goyal, S. , Jamal, S. , Somvanshi, P. , & Grover, A. (2016). Fragment based G-QSAR and molecular dynamics based mechanistic simulations into hydroxamic-based HDAC inhibitors against spinocerebellar ataxia. Journal of Biomolecular Structure and Dynamics , 34 , 2281–2295. doi:10.1080/07391102.2015.1113386
   PubMed Web of Science ®Google Scholar
• Su, P.-C. , & Johnson, M. E. (2015). Evaluating thermodynamic integration performance of the new amber molecular dynamics package and assess potential halogen bonds of enoyl-ACP reductase (FabI) benzimidazole inhibitors. Journal of Computational Chemistry , 37 , 836–847. doi:10.1002/jcc.24274
   PubMed Web of Science ®Google Scholar
• Su, P.-C. , Tsai, C.-C. , Mehboob, S. , Hevener, K. E. , & Johnson, M. E. (2015). Comparison of radii sets, entropy, QM methods, and sampling on MM-PBSA, MM-GBSA, and QM/MM-GBSA ligand binding energies ofF. tularensisenoyl-ACP reductase (FabI). Journal of Computational Chemistry , 36 , 1859–1873. doi:10.1002/jcc.24011
   PubMed Web of Science ®Google Scholar
• Takahashi, Y. , Hibi, S. , Hoshino, Y. , Kikuchi, K. , Shin, K. , Murata-Tai, K. , … Yonaga, M. (2012). Synthesis and structure–activity relationships of pyrazolo [1, 5-a] pyridine derivatives: Potent and orally active antagonists of corticotropin-releasing factor 1 receptor. Journal of Medicinal Chemistry , 55 , 5255–5269. doi:10.1021/jm300259r
   PubMed Web of Science ®Google Scholar
• Takeda, K. , Terauchi, T. , Shin, K. , Ino, M. , Shibata, H. , & Yonaga, M. (2012). Design, synthesis and structure–activity relationships of 5-alkylaminolquinolines as a novel series of CRF 1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters , 22 , 4756–4761. doi:10.1016/j.bmcl.2012.05.066
   PubMed Web of Science ®Google Scholar
• Tripuraneni, N. S. , & Azam, M. A. (2016). A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors. Journal of Biomolecular Structure and Dynamics , 34 , 2481–2492. doi:10.1080/07391102.2015.1119732
   PubMed Web of Science ®Google Scholar
• VLife MDS . VLife Science technologies. Pune, India.
   Google Scholar
• Webster, E. L. , Lewis, D. B. , Torpy, D. J. , Zachman, E. K. , Rice, K. C. , & Chrousos, G. P. (1996). In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology , 137 , 5747–5750. doi:10.1210/en.137.12.5747.
   PubMed Web of Science ®Google Scholar
• Williams, J. P. (2013). Corticotropin-releasing factor 1 receptor antagonists: a patent review. Expert Opinion on Therapeutic Patents , 23 , 1057–1068. doi:10.1517/13543776.2013.795545.
   PubMed Web of Science ®Google Scholar
• Zhou, S. , Fang, D. , Tan, S. , Lin, W. , Wu, W. , & Zheng, K. (2016). Investigating the binding mechanism of novel 6-aminonicotinate-based antagonists with P2Y12 by 3D-QSAR, docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics , 1–28 , doi:10.1080/07391102.2016.1237381
   Web of Science ®Google Scholar
• Zorrilla, E. P. , & Koob, G. F. (2004). The therapeutic potential of CRF1 antagonists for anxiety. Expert Opinion on Investigational Drugs , 13 , 799–828. doi:10.1517/13543784.13.7.799
   PubMed Web of Science ®Google Scholar
• Zoumakis, E. , Rice, K. C. , Gold, P. W. , & Chrousos, G. P. (2006). Potential uses of corticotropin-releasing hormone antagonists. Annals of the New York Academy of Sciences , 1083 , 239–251. doi:10.1196/annals.1367.021
   PubMed Web of Science ®Google Scholar